NVO Novo Nordisk A/S NYSE down 14.64% pre-market Feb 2026: guidance trims value

NVO stock dropped 14.64% in pre-market trading to $50.30 after management issued a cautious 2026 outlook ahead of the Feb 4 earnings call. The move followed a beat on Q4 revenue and EPS but a softer-than-expected forward guide, driving heavy volume of 69,273,791 shares and a 1‑day change of -8.63. Investors will watch guidance details when Novo Nordisk A/S (NVO) reports at the scheduled earnings announcement and parse how the Diabetes and Obesity Care business will affect full‑year USD sales and margin assumptions.